CINECA IRIS Institutional Research Information System
IRIS è la soluzione IT che facilita la raccolta e la gestione dei dati relativi alle attività e ai prodotti della ricerca. Fornisce a ricercatori, amministratori e valutatori gli strumenti per monitorare i risultati della ricerca, aumentarne la visibilità e allocare in modo efficace le risorse disponibili.
EnglishAbstract Few studies have addressed longer-term survival for breast cancer in European women. We have made predictions of ten-year survival for European women diagnosed with breast cancer in 2000-2002. Data for 114,312 adult women (15-99 years) diagnosed with a first primary malignant cancer of the breast during 2000-2002 were collected in the EUROCARE-4 study from 24 population-based cancer registries in 14 European countries. We estimated relative survival at one, five and ten years after diagnosis for women who were alive at some point during 2000-2002, using the period approach. We also estimated ten-year survival conditional on survival to one and five years after diagnosis. Ten-year survival exceeded 70% in most regions, but was only 54% in Eastern Europe, with the highest value in Northern Europe (about 75%). Ten-year survival conditional on survival for one year was 2%-6% higher than ten-year survival in all European regions, and geographic differences were smaller. Ten-year survival for women who survived at least five years was 88% overall, with the lowest figure in Eastern Europe (79%) and the highest in the UK (91%). Women aged 50-69 years had higher overall survival than older and younger women (79%). Six cancer registries had adequate information on stage at diagnosis; in these jurisdictions, 10-year survival was 89% for local, 62% for regional and 10% for metastatic disease. Data on stage are not collected routinely or consistently, yet these data are essential for meaningful comparison of population-based survival, which provides vital information for improving breast cancer control.
Scheda prodotto non validato
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo
| Titolo: | Predictions of survival up to 10 years after diagnosis for european women with breast cancer in 2000-2002. |
| Autori: | |
| Data di pubblicazione: | 2013 |
| Rivista: | |
| Citazione: | Predictions of survival up to 10 years after diagnosis for european women with breast cancer in 2000-2002. / ALLEMANI C; MINICOZZI P; BERRINO F; BASTIAANNET E; GAVIN A; GALCERAN J; AMEIJIDE A; SIESLING S; MANGONE L; ARDANAZ E; HÉDELIN G; MATEOS A; MICHELI A; SANT M; THE EUROCARE WORKING GROUP; VERCELLI M.. - In: INTERNATIONAL JOURNAL OF CANCER. - ISSN 0020-7136. - STAMPA. - 132(2013), pp. 2404-2412. |
| Abstract: | Abstract Few studies have addressed longer-term survival for breast cancer in European women. We have made predictions of ten-year survival for European women diagnosed with breast cancer in 2000-2002. Data for 114,312 adult women (15-99 years) diagnosed with a first primary malignant cancer of the breast during 2000-2002 were collected in the EUROCARE-4 study from 24 population-based cancer registries in 14 European countries. We estimated relative survival at one, five and ten years after diagnosis for women who were alive at some point during 2000-2002, using the period approach. We also estimated ten-year survival conditional on survival to one and five years after diagnosis. Ten-year survival exceeded 70% in most regions, but was only 54% in Eastern Europe, with the highest value in Northern Europe (about 75%). Ten-year survival conditional on survival for one year was 2%-6% higher than ten-year survival in all European regions, and geographic differences were smaller. Ten-year survival for women who survived at least five years was 88% overall, with the lowest figure in Eastern Europe (79%) and the highest in the UK (91%). Women aged 50-69 years had higher overall survival than older and younger women (79%). Six cancer registries had adequate information on stage at diagnosis; in these jurisdictions, 10-year survival was 89% for local, 62% for regional and 10% for metastatic disease. Data on stage are not collected routinely or consistently, yet these data are essential for meaningful comparison of population-based survival, which provides vital information for improving breast cancer control. |
| Handle: | http://hdl.handle.net/11567/490718 |
| Appare nelle tipologie: | 01.01 - Articolo su rivista |
File in questo prodotto:
http://hdl.handle.net/11567/490718
Copyright © 2020